ATE224184T1 - Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe - Google Patents

Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe

Info

Publication number
ATE224184T1
ATE224184T1 AT94930794T AT94930794T ATE224184T1 AT E224184 T1 ATE224184 T1 AT E224184T1 AT 94930794 T AT94930794 T AT 94930794T AT 94930794 T AT94930794 T AT 94930794T AT E224184 T1 ATE224184 T1 AT E224184T1
Authority
AT
Austria
Prior art keywords
vaccines
compositions
antigens
microspheres
microencapsulating antigens
Prior art date
Application number
AT94930794T
Other languages
English (en)
Inventor
Jeffrey L Cleland
Amy Lim
Michael Frank Powell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE224184T1 publication Critical patent/ATE224184T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT94930794T 1993-10-22 1994-10-13 Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe ATE224184T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14179693A 1993-10-22 1993-10-22
US14355593A 1993-10-25 1993-10-25
PCT/US1994/011753 WO1995011010A1 (en) 1993-10-22 1994-10-13 Methods and compositions for microencapsulation of antigens for use as vaccines

Publications (1)

Publication Number Publication Date
ATE224184T1 true ATE224184T1 (de) 2002-10-15

Family

ID=26839455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930794T ATE224184T1 (de) 1993-10-22 1994-10-13 Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe

Country Status (9)

Country Link
EP (1) EP0724432B1 (de)
JP (1) JPH09504027A (de)
AT (1) ATE224184T1 (de)
AU (1) AU7980794A (de)
CA (1) CA2172509C (de)
DE (1) DE69431404T2 (de)
DK (1) DK0724432T3 (de)
ES (1) ES2184769T3 (de)
WO (1) WO1995011010A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
JP3841309B2 (ja) * 1993-10-22 2006-11-01 ジェネンテック・インコーポレーテッド 流動床乾燥工程を含んでなるミクロスフェアの製造方法
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
GB2317340B (en) * 1995-07-13 1998-12-23 Danbiosyst Uk Polymeric lamellar substrate particles for drug delivery
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
EP1579851A3 (de) * 1997-08-29 2009-09-02 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben
WO1999009956A1 (en) * 1997-08-29 1999-03-04 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
US6086901A (en) * 1997-12-16 2000-07-11 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
CN1242750C (zh) * 2000-02-08 2006-02-22 分子农业生物学院 可生物降解的且生物相容的封装有肠炎沙门氏菌的聚合物微球体
ES2160089B1 (es) * 2000-03-15 2002-05-16 Inst Cientifico Tecnol Navarra Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos.
US6565888B1 (en) * 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
EP1417236A4 (de) * 2001-07-10 2010-03-17 Corixa Corp Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel
PL376476A1 (en) 2002-10-24 2005-12-27 Merz Pharma Gmbh & Co.Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
KR20060030469A (ko) 2003-05-27 2006-04-10 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 nmda수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
CN100342916C (zh) * 2004-12-08 2007-10-17 上海第二医科大学附属第九人民医院 一种可生物降解医用材料标记物及其制备
CN101437539B (zh) 2005-07-05 2013-10-02 康奈尔研究基金会(有限公司) 通过干扰cd99l2阻断白细胞迁出和炎症
KR20080047395A (ko) 2005-08-25 2008-05-28 다이호야쿠힌고교 가부시키가이샤 T세포 인식 에피토프 펩티드를 고정화 또는 내포화한생분해성 나노입자
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8877814B2 (en) 2007-09-12 2014-11-04 Merz Pharma Gmbh & Co. Kgaa Titration package for neramexane and its use in the treatment of an inner ear disorder
ES2358703B1 (es) * 2007-11-14 2012-03-21 Universidad Del Pais Vasco Empleo de micropart�?culas para su uso como vacunas y la liberación de moléculas biológicamente activas.
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
EP2085120A1 (de) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Verwendung von Substanzen zur Behandlung zentraler und peripherer Insulinrezeptorbeeinträchtigung oder Insulinresistenz
EP2318832B1 (de) 2008-07-15 2013-10-09 Academia Sinica Glycan-arrays auf objektträgern mit ptfe-aluminiumbeschichtung und entsprechende verfahren
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US20120136005A1 (en) 2009-06-30 2012-05-31 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
US20120190690A1 (en) 2009-06-30 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110294890A1 (en) 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
WO2012098000A1 (en) 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
WO2012171653A1 (en) 2011-06-15 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd)
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
TW201412325A (zh) 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CN104869981B (zh) * 2012-11-09 2018-05-08 赢创有限公司 用于协调微粒性质的干燥方法
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10300136B2 (en) * 2013-12-16 2019-05-28 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
WO2015095185A1 (en) 2013-12-16 2015-06-25 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
EP3129767B1 (de) 2014-03-27 2021-09-01 Academia Sinica Reaktive markierungsverbindungen und ihre verwendungen
KR20170005142A (ko) 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
EP3149036A4 (de) 2014-05-27 2017-12-27 Academia Sinica Anti-cd20-glycoantikörper und verwendungen davon
EP3149037A4 (de) 2014-05-27 2018-01-10 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗TNFα糖操作抗体群およびその使用
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類iNKT細胞
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
CN108350605A (zh) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018071683A2 (pt) 2016-04-22 2019-02-19 Obi Pharma, Inc. método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
WO2018013797A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
EP3791873A1 (de) 2019-09-16 2021-03-17 Universite De Bordeaux Verfahren zur behandlung und/oder vorbeugung von erkrankungen und symptomen im zusammenhang mit bkca- und/oder sk-kanalophathien
AU2022226584A1 (en) 2021-02-24 2023-08-17 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3855869T2 (de) * 1987-02-20 1997-10-02 Genentech Inc Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
CA2172509A1 (en) 1995-04-27
DE69431404D1 (de) 2002-10-24
EP0724432A1 (de) 1996-08-07
AU7980794A (en) 1995-05-08
JPH09504027A (ja) 1997-04-22
DK0724432T3 (da) 2003-01-27
CA2172509C (en) 2010-08-24
ES2184769T3 (es) 2003-04-16
WO1995011010A1 (en) 1995-04-27
EP0724432B1 (de) 2002-09-18
DE69431404T2 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
ATE224184T1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE69431358T2 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
ATE466869T1 (de) Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
DE68918142T2 (de) Zusammensetzungen und Verfahren zur kontrollierten Freisetzung von Duftstoffen.
BR9809656A (pt) Composição imunopotencializante
DK1042001T3 (da) Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner
DE69231837T2 (de) Antigen praesentierende ms2-huelle
ITMI920168A0 (it) Sistemja e metodo per controllare le vibrazioni sincrone di palette
DE3486160T2 (de) Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben.
DK0585943T3 (da) Opløselige ligander for CD40
DE60004496D1 (de) Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
ATE249840T1 (de) Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
DK0885244T3 (da) Peptidimmunogener til vaccination imod og til behandling af allergi
DK0668772T3 (da) Specifik immunsystemmodulering
DE59001862D1 (de) Verfahren und mahlanlage zur zweistufigen zerkleinerung von sproedem mahlgut.
ATE101876T1 (de) Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern.
ATE416787T1 (de) Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
DK0728015T3 (da) Kombinatoriske polypeptidantigener
MX9203574A (es) Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen.
ATE152916T1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind
DK0542895T3 (da) Krydsreaktiv influenza A immunisering

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification